• Biome reports its first net profit of $96,228 (excluding R&D rebate) or $433,395 (including R&D rebate)
• Biome achieved positive EBITDA of $351,765 (excluding R&D rebate and share-based payments)
• Biome reports record half-year and quarterly sales revenue of $8.86m and $4.6m respectively

Microbiome health company Biome Australia Limited (ASX: BIO) has released its Appendix 4D and Half Yearly Report for the half year ended 31 December 2024. Biome is pleased to report that in H1, the company achieved its maiden net profit of $96,228, or $433,395, including the annual R&D rebate. Sales revenue for the half reached a new record of $8.86m and EBITDA of $351,765 (excluding R&D rebate) for H1 FY25, growing from $121,848 in Q1 to $229,917 in Q2, an 89% increase. Biome increased its gross margin to 61% through the period, an increase from 60% (+1%) vs PCP. The start of FY25 has brought a significant increase in Biome Australia's distribution footprint, with a 20% increase, reaching 6000 distribution points at 31 December 2024. Biome released Vision 27 during the Half, a comprehensive three-year strategic plan to deliver significant growth domestically and scale internationally, providing the market with revenue guidance of up to $85m in cumulative sales revenue from FY25-FY27. Biome also launched its new cholesterol-lowering probiotic, Biome Cholesterol™ Probiotic in Q1 FY25 and successfully launched into Canada with Ecotrend Ecologics in September 2024.

Biome released Vision 27 during the Half, providing the market with revenue guidance of up to $85m in cumulative sales revenue from FY25-FY27.

Biome is seeing strong initial traction in Canada, and other international markets are developing well. A comprehensive international market update will be provided during the year. Biome is preparing final plans to launch its new brand and will share the product range and health targets in Q4 FY25.